On Brink of Phase III, Sophiris Files IPO to Advance BPH Bid
By Randy Osborne
Tuesday, February 19, 2013
Aiming to start pivotal trials with its therapy for benign prostatic hyperplasia (BPH) before the end of the year, Sophiris Bio Inc. (formerly Protox Therapeutics Inc.) filed for an initial public offering (IPO) that specifies neither the number of shares nor the price range.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.